| Literature DB >> 34177818 |
Xiaojing Wang1, Yufei Lyu1, Siya Wang1,2, Qingfang Zheng1,3, Erling Feng1, Li Zhu1, Chao Pan1, Shenghou Wang2, Dongshu Wang1, Xiankai Liu1, Hengliang Wang1.
Abstract
The CRISPR-Cas system has been widely applied in prokaryotic genome editing with its high efficiency and easy operation. We constructed some "scissors plasmids" via using the temperature-sensitive pJOE8999 shuttle plasmid, which carry the different 20nt (N20) guiding the Cas9 nuclease as a scissors to break the target DNA. We successfully used scissors plasmids to eliminate native plasmids from Bacillus anthracis and Bacillus cereus, and specifically killed B. anthracis. When curing pXO1 and pXO2 virulence plasmids from B. anthracis A16PI2 and A16Q1, respectively, we found that the plasmid elimination percentage was slightly higher when the sgRNA targeted the replication initiation region (96-100%), rather than the non-replication initiation region (88-92%). We also tried using a mixture of two scissors plasmids to simultaneously eliminate pXO1 and pXO2 plasmids from B. anthracis, and the single and double plasmid-cured rates were 29 and 14%, respectively. To our surprise, when we used the scissor plasmid containing two tandem sgRNAs to cure the target plasmids pXO1 and pXO2 from wild strain B. anthracis A16 simultaneously, only the second sgRNA could guide Cas9 to cleave the target plasmid with high efficiency, while the first sgRNA didn't work in all the experiments we designed. When we used the CRISPR/cas9 system to eliminate the pCE1 mega-virulence plasmid from B. cereus BC307 by simply changing the sgRNA, we also obtained a plasmid-cured isogenic strain at a very high elimination rate (69%). The sterilization efficiency of B. anthracis was about 93%, which is similar to the efficiency of plasmid curing, and there was no significant difference in the efficiency of among the scissors plasmids containing single sgRNA, targeting multi-sites, or single-site targeting and the two tandem sgRNA. This simple and effective curing method, which is applicable to B. cereus group strains, provides a new way to study these bacteria and their virulence profiles.Entities:
Keywords: B. cereus group; CRISPR/Cas9; plasmid curing; sequence-specific antimicrobials; sgRNA; virulence plasmid
Year: 2021 PMID: 34177818 PMCID: PMC8222586 DOI: 10.3389/fmicb.2021.536357
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Plasmids and strains used in this study.
| pJOE8999 | Contains CRISPR-Cas9 system plasmid for breaking genome; Kanamycin (30 μg/mL) | Altenbuchner, |
| pJO1T | pJOE8999 plasmid containing sgRNA sequence target to the replication initiation region of pXO1 plasmid in | This study |
| pJO2T | pJOE8999 plasmid containing sgRNA sequence target to the replication initiation region of pXO2 plasmid in | This study |
| pJO1NT | pJOE8999 plasmid containing sgRNA sequence target to the non-replication initiation region of pXO1 plasmid in | This study |
| pJO2NT | pJOE8999 plasmid containing sgRNA sequence target to the non-replication initiation region of pXO2 plasmid in | This study |
| pJN1F2T | pJOE8999 plasmid successively containing O1NT, ‘gRNA and O2T, the two sgRNA sharing with a promoter P | This study |
| pJF2N1T | pJOE8999 plasmid successively containing O2T, ‘gRNA and O1NT, the two sgRNA sharing with a promoter P | This study |
| pJN1F2W | pJOE8999 plasmid successively containing O1NT, ‘gRNA-ter, P | This study |
| pJF2N1W | pJOE8999 plasmid successively containing O2T,'gRNA-ter, P | This study |
| pJ16ST | pJOE8999 plasmid containing sgRNA sequence target to 16S rRNA of | This study |
| pJART | pJOE8999 plasmid containing sgRNA sequence target to a specific DNA fragment of the chromosome of | This study |
| pJHNT | pJOE8999 plasmid containing sgRNA sequence target to a specific DNA fragment of the chromosome of | This study |
| pJA16SRT | pJOE8999 plasmid containing two sgRNAs sequence targeting on 16S rRNA (16ST) and non-replication initiation region of a specific DNA fragment of the chromosome in | This study |
| pJA16SRTW | pJOE8999 plasmid containing two sgRNAs sequence targeting on 16S rRNA and non- replication initiation region of a specific DNA fragment of the chromosome in | This study |
| pJp1T | pJOE8999 plasmid containing sgRNA sequence target to pCE1 plasmid of | This study |
| pXO2 plasmid-cured derivative of wild type A16 using Plasmid Incompatibility; pXO1+, pXO2− | Wang et al., | |
| A16PI2 contains recombinant plasmid pJO1T; pXO1+, pJO1T+ | This study | |
| pXO1 plasmid-cured derivative of A16PI2 using CRISPR/Case9 system; pXO1− | This study | |
| pXO1 plasmid-cured derivative of wild type A16 using plasmid incompatibility; pXO1−, pXO2+ | Liu et al., | |
| A16Q1 contains recombinant plasmid pJO2T; pXO2+ pJO2T+ | This study | |
| pXO2 plasmid-cured derivative of A16Q1 using CRISPR/Cas9 system; pXO2− | This study | |
| Wild type A16 isolated from the carcass of a mule that died from anthrax in Hebei Province, China, in 1953; pXO1+, pXO2+ | This lab | |
| A16 contains recombinant plasmid pJO1T and pJO2T; pXO1+pXO2+ pJO1T+ pJO2T+ | This study | |
| pJN1F2T/A16 | A16 contains recombinant plasmid pJN1F2T: pXO1+pXO2+ pJN1F2T+ | This study |
| pJF2N1T/A16 | A16 contains recombinant plasmid pJF2N1T: pXO1+pXO2+ pJF2N1T+ | This study |
| pJN1F2W/A16 | A16 contains recombinant plasmid pJN1F2TW: pXO1+pXO2+ pJN1F2TW+ | This study |
| pJF2N1W/A16 | A16 contains recombinant plasmid pJF2N1TW: pXO1+pXO2+ pJF2N1W+ | This study |
| pXO1 plasmid-cured derivative of wild type A16 using CRISPR/Cas9 system; pXO1− pXO2+ | This study | |
| pXO2 plasmid-cured derivative of wild type A16 using CRISPR/Cas9 system; pXO1+ pXO2− | This study | |
| pXO1 and pXO2 plasmid-cured derivative of wild type A16 using CRISPR/Cas9 system; pXO1− pXO2− | This study | |
| pJ16ST/A16PI2 | A16PI2 contains recombinant plasmid pJ16ST | This study |
| pJART/A16PI2 | A16PI2 contains recombinant plasmid pJART | This study |
| pJA16sRT/A16PI2 | A16PI2 contains recombinant plasmid pJ16sRT | This study |
| pJA16sRTW/A16PI2 | A16PI2 contains recombinant plasmid pJ16sRTW | This study |
| This lab | ||
| pJART/HN001 | HN001 contains recombinant plasmid pJART | This study |
| This lab | ||
| pJp1T/BC307 | BC307 contains recombinant plasmid pJp1T | This study |
| pCE1 plasmid-cured derivative of BC307 using CRISPR/Cas9 system; pCE1− | This study | |
The semisynthetic promoter. The sgRNA transcribed from the semisynthetic promoter P
interrupted by the lacZ α fragment (lacPOZ').
Oligonucleotide sequences and primers used in this study.
| O1T and PAM: | ATAACTTGTAATAGCCCTTT | N20 sequence and PAM on pXO1 origin of DNA replication |
| O2T and PAM: | ACACAAAGTGATAGCCTAGA | N20 sequence and PAM on pXO2 origin of DNA replication |
| FO1T | TACG ATAACTTGTAATAGCCCTTT | O1T sequence 5′ end plus TACG connector |
| RO1T | AAAC AAAGGGCTATTACAAGTTAT | O1T reverse complementary sequence 5′ end plus AAAC linker |
| FO2T | TACG ACACAAAGTGATAGCCTAGA | O2T sequence 5′ end plus TACG connector |
| RO2T | AAAC TCTAGGCTATCACTTTGTGT | O2T reverse complementary sequence 5′ end plus AAAC linker |
| O1NTand PAM | TATTCGATGAAGTCATACAC | N20 sequence and PAM on pXO1 non-origin of DNA replication |
| O2NTand PAM | CTACTTATAAGAACAAACCG | N20 sequence and PAM on pXO2 non-origin of DNA replication |
| FO1NT | TACG TATTCGATGAAGTCATACAC | O1NT sequence 5′ end plus TACG connector |
| RO1NT | AAAC GTGTATGACTTCATCGAATA | O1NT reverse complementary sequence 5′ end plus AAAC linker |
| FO2NT | TACG CTACTTATAAGAACAAACCG | O2NT sequence 5′ end plus TACG connector |
| RO2NT | AAAC CGGTTTGTTCTTATAAGTAG | O2NT reverse complementary sequence 5′ end plus AAAC linker |
| 16ST and PAM | CGTGAGTGATGAAGGCTTTC | N20 sequence targeting the 16SrNA region of |
| ART and PAM | ACACGGATGATAATAATTTG | |
| Spacer-F | AACCATCACTGTACCTCCCA | Two BsaI outer primers on pJOE8999, verifying whether N20 is successfully linked |
| Spacer-R | GAGCGTTCTGAACAAATCCA | |
| pJOE8999-F | TAGTGTAGCCGTAGTTAGG | Specific sequence primers on pJOE8999 to verify the presence of pJOE8999 |
| pJOE8999-R | AAAGGGAATGAGAATAGTG | |
| cya-F | AGGATTGATGTGCTGAAAGGAG | cya gene primer pair on pXO1 |
| cya-R | TTCGTCTTTGTCGCCACTATC | |
| pXO1-7F | CGTACTGCTGGAATTGATGG | A specific gene primer pair on pXO1 |
| pXO1-7R | GTCTTGGCTAACACCTGTATG | |
| pXO1-13F | AGAAATTGAGTTTGAATATGGTGAG | A specific gene primer pair on pXO1 |
| pXO1-13R | AGGTTGGCTTACTGGAGATAC | |
| pXO1-16F | AGCACATGACATACGAAGAAC | A specific gene primer pair on pXO1 |
| pXO1-16R | GAACATAAGAAGTCTGAATGGATAG | |
| pXO1-23F | AACTAAGACACAACGAATACTACG | A specific gene primer pair on pXO1 |
| pXO1-23R | CATTATGTGGTCAAGATTATGGTTC | |
| pXO1-32F | TGAACATGAACTAGAGGAATTGG | A specific gene primer pair on pXO1 |
| pXO1-32R | ATCTTCTGGAGTCGGATTAGC | |
| pXO1-42F | ATCTGTGCTGCTCGTATCG | A specific gene primer pair on pXO1 |
| pXO1-42R | GGAATCCTGGAATGAATGATGG | |
| pXO1-51F | TTGCCTGAGGTTCCTGTTG | A specific gene primer pair on pXO1 |
| pXO1-51R | GCTTTCTCTCCCTTTGTGTAAG | |
| pXO1-55F | CGAATGAAGGTTATTGGAATAGC | A specific gene primer pair on pXO1 |
| pXO1-55R | CTGGATCTGGATTAGGTGTTAC | |
| pXO1-59F | GGACTCGGAACAACAATAACG | A specific gene primer pair on pXO1 |
| pXO1-59R | CCTCTCCATTTCGGCTGAC | |
| pXO1-67F | AATGGGAATCAAAGTTTACAATCTG | A specific gene primer pair on pXO1 |
| pXO1-67R | ACTGAACACCACCTACCTTATC | |
| pXO1-70F | CATACCATTACAGGAGCATCATC | A specific gene primer pair on pXO1 |
| pXO1-70R | ACCAGGAATCGCAAGAACC | |
| pXO1-90F | AAGGAAGTAGAGGCAGAAGC | A specific gene primer pair on pXO1 |
| pXO1-90R | TTAATGTGTTGGCGTTCAGG | |
| pXO1-95F | GTCTATCAGAAGTAGGTCATAACG | A specific gene primer pair on pXO1 |
| pXO1-95R | TTCAGTAAGAGCCTCCATAGTAG | |
| pXO1-98F | GACTGGTATTTCTACTGGGTTTG | A specific gene primer pair on pXO1 |
| pXO1-98R | GTCCTGCTTCTTGATGATGATG | |
| pXO1-116F | CCTTCGTTCTGGTGATATGTG | A specific gene primer pair on pXO1 |
| pXO1-116R | AATAATATGTGGTGCCTCTTCTG | |
| pXO1-133F | ATTGTGGAGGATAGATTCTTTGG | A specific gene primer pair on pXO1 |
| pXO1-133R | TCTCGCTTGGCTAATTTCATC | |
| pXO1-142F | CGTGGACATCTGCTTGAAC | A specific gene primer pair on pXO1 |
| pXO1-142R | GACGACCTTCCTCTTGATATTG | |
| capA-F | CGATGACGATGGGTGAC | capA gene primer pair on pXO2 |
| capA-R | AGATTGAAGTACATGCGGATGG | |
| pXO2-007F | GCGATGGTGGAACAGGAATG | A specific gene primer pair on pXO2 |
| pXO2-007R | TGCGTTGCTGCCGATATTG | |
| pXO2-016F | CGGTTTGGTATGAGTGAGGAAG | A specific gene primer pair on pXO2 |
| pXO2-016R | ATTGGCTGTGGTGGTTGTTG | |
| pXO2-023F | TTGGGACAGGCGTTATAGAAAG | A specific gene primer pair on pXO2 |
| pXO2-023R | GCAGCGAAGTCACTACATGG | |
| pXO2-027F | GTGGACTTCCTGTAACCGTAAG | A specific gene primer pair on pXO2 |
| pXO2-027R | ATGTAATGGCTGCGTCACTTC | |
| pXO2-039F | GCTTCTCACTGGACACCTAATG | A specific gene primer pair on pXO2 |
| pXO2-039R | CCACTCGTGCCAATGACTAC | |
| pXO2-060F | CGAAAGCAACAGGGATACAAAG | A specific gene primer pair on pXO2 |
| pXO2-060R | AGATACTCTGCCCAACTTTCAC | |
| pXO2-084F | AGCGTTCAAATACAGTCACATC | A specific gene primer pair on pXO2 |
| pXO2-084R | TTACCTTTGCGATTTCCTCATC | |
| pXO2-089F | AACTGACGGTGAATCCATGAAC | A specific gene primer pair on pXO2 |
| pXO2-089R | ATTGCCTGACTAATCGCTAAGC | |
| pXO2-094F | CCTGGGCGTAAAGAAGATGG | A specific gene primer pair on pXO2 |
| pXO2-094R | TCTCGTTGCGTGACATTATCG | |
| pXO2-097F | AAGCAACCCGTGGAGATTTC | A specific gene primer pair on pXO2 |
| pXO2-097R | TGGATGTTCCGCACCTTTATAG | |
| pXO2-107F | TGGACGGAGAACAGGACTATG | A specific gene primer pair on pXO2 |
| pXO2-107R | GGGCTTGCGGATACTCAGG | |
| pXO2-111F | ATACAAGCGAAGCATCAGTACC | A specific gene primer pair on pXO2 |
| pXO2-111R | TCCATCGTTACAACCTCCATTC | |
| p1Tand PAM | AACTCCTAGTCAAGTACCAT | N20 sequence and PAM on |
| Fp1T | TACG AACTCCTAGTCAAGTACCAT | p1T sequence 5′ end plus TACG connector |
| Rp1T | AAAC ATGGTACTTGACTAGGAGTT | p1T reverse complementary sequence 5′ end plus AAAC linker |
| P | GTGATTAGAGAATTGAGTAAAATGTACCTACG | The promoter from the pJOE8999 plasmid |
| ‘gRNA | GCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTA | The gRNA from the pJOE8999 plasmid |
| Ter | ACTCCATCTGGATTTGTTCAGAACGCTC | The terminator of opp from the pJOE8999 plasmid |
| cesA-F | TTCGGTGTTACTGTGTCTG | A specific gene (cesA gene) primer pair on |
| cesA-F | ATCGCATTCTCTTCCATCC | |
| cesB-F | AACTTCAACCACAGGACAA | A specific gene (cesB gene) primer pair on |
| cesB-R | ACATTACTATACCGCCAACA | |
| cesC-F | CATGTCGGCTATCTTCCAG | A specific gene (cesC gene) primer pair on |
| cesC-R | GCAACCAGATTCTCCACTT | |
| cesD-F | GTGACAAGACCATTAGACC | A specific gene (cesD gene) primer pair on |
| cesD-R | ACCTGAGACGATTAGTAGTA | |
| cesH-F | TCTGTTGTGGCAATAGGT | A specific gene (cesH gene) primer pair on |
| cesH-R | GGAATGATAACTCCTTGACA | |
| cesP-F | AGGTGTGGATGTGGAGAA | A specific gene (cesP gene) primer pair on |
| cesP-R | GATTGTCGGTCAGCCTAC | |
| cesT-F | CAGGCGGAAGTGCTAATG | A specific gene (cesT gene) primer pair on |
| cesT-R | GTCCTCCTTCATAATGTATCAG | |
| p1-01F | AACCAAGCATACAGTCTCTT | A specific gene primer pair on |
| p1-01R | CGTTGACCACTATCACCAT | |
| p1-02F | CGTTCTTATGTAGCCGATGT | A specific gene primer pair on |
| p1-02R | GCTTCCTGTTATCACCACTA | |
| p1-03F | GGGTTTGGGTATCCGTAAT | A specific gene primer pair on |
| p1-03R | ATGATTGGCGAAGAAGTGT | |
| p1-04F | CAGCACCTATCCAATTACCA | A specific gene primer pair on |
| p1-04R | CATATTCAATCTCCATCCATCC | |
| p1-05F | CAGGAGACCAAGCACATC | A specific gene primer pair on |
| p1-05R | CAAGAATATACTCGCTCAGAC | |
| p1-06F | GGTGGAGGAACAGGAACT | A specific gene primer pair on |
| p1-06R | ATCGTCAGCAACTTCTACTT | |
| p1-07F | GAGAAGGCGATTGAAGGA | A specific gene primer pair on |
| p1-07R | CCAGAGTGTAATGTCTTGTT | |
| p1-08F | CGAATAGCAGAGCCTGATAT | A specific gene primer pair on |
| p1-08R | GGTAATCCAGAAGTGAATGTAG |
The underlined part is the PAM sequence.
Figure 1Colony PCR for pJO1T, pJO2T, pJO1NT, pJO2NT, pJN1F2T, pJF2N1T, pJN1F2W, and pJF2N1W constructs in Escherichia coli DH5α with primer pair spacer-F/R. M, Trans2K Plus II DNA marker. (A) The expected sizes of the fragments from pJO1T, pJO2T, pJO1NT, and pJO2NT are smaller than those from the pJOE8999 negative control. (B) The expected sizes of the fragments from pJO1T, pJO2T, pJO1NT, and pJO2NT are smaller than those from the pJOE8999 negative control. (C) The constructing process of the recombinant plasmid with two sgRNAs of O1NT and O2T inserted into pJOE8999 in tandem.
Figure 2Colony PCR for screening scissors plasmid transformants in Bacillus anthracis with primer pair pJOE8999-F/R. M, Trans2K Plus II DNA marker. (A,B) Escherichia coli SCS110 containing a recombinant plasmid was the active control. The expected sizes of the fragments from the constructed strains are consistent with the size of the amplified fragments from the active control strain.
Figure 3Preliminary PCR screening of colonies for pXO1 and pXO2 plasmid-cured strains with cya-F/R and capA-F/R primers, respectively. (A) Colony PCR with cya-F/R after curing the pXO1 plasmid from pJO1T/A16PI2 and pJO1NT/A16PI2. The pXO1 plasmid-cured strains do not have a specific amplification fragment, and the efficiency of pJO1T was about 96% (expect lane 23). The efficiency of pJO1NT was about 92% (expect lanes 14, 16). (B) Colony PCR with capA-F/R after curing the pXO2 plasmid from pJO2T/A16Q1 and pJO2NT/A16Q1. The pXO2 plasmid-cured strains do not have a specific amplification fragment, and the efficiency of pJO2T was about 100%. The efficiency of pJO2NT was about 88% (except lanes 5, 21, 22). (C) Colony PCR with capC-F/R (lane a) and pag-F/R primers (lane b) to screen for plasmid-cured strains from A16. The simultaneously cured pXO1 and pXO2 plasmids in A16 do not have specific amplification fragments in lanes a and b (1 and 7 monoclonal colonies). The pXO1 plasmid-cured strains in A16 do not have a specific amplification fragment in lane b but have a specific amplification fragment in lane a (2–6 monoclonal colonies). The pXO2 plasmid-cured strains in A16 do not have a specific amplification fragment in lane a, but have a specific amplification fragment in lane b (8–12 monoclonal colonies). (D) The efficiency of curing plasmids from B. anthracis A16 by using the recombinant plasmid with two sgRNAs of O1NT and O2T inserted into pJOE8999 in tandem. Colony PCR was revealed for pXO1 and pXO2 plasmid-cured strains with cya-F/R and capA-F/R. After with 0.4% D-mannose, the random 11 clones of pJN1F2T/A16, pJN1F2W/A16, pJF2N1T/A16, and pJF2N1W/A16 were used to assaying the curing rate. The curing pXO2 efficiency of pJN1F2T/A16 and pJN1F2W/A16 were respectively ~91 and 100%, and they both do not cure the pXO1. The curing pXO1 efficiency of pJF2N1T/A16 and pJF2N1W/A16 were respectively ~100 and 72%, and they both do not cure the pXO2. M, Trans2K Plus II DNA marker; lane1-11, 11 samples; +, control.
Figure 4Agarose gel electrophoretogram of colony PCR to confirm the successful elimination of the exogenous scissors plasmid. M, Trans2K Plus II DNA marker. The exogenous scissors plasmid-eliminated strains (A16PI2D1, A16Q1D2, A16MD1, A16MD2, and A16MDD) lack specific amplification fragments, while the active pJOE8999 control plasmid generated specific amplification fragments.
Figure 5Agarose gel electrophoresis of colony PCR to identify plasmid curing via multiple primers. (A) The authenticity of the A16PI2D1 pXO1-cured strain was confirmed using 17 primer pairs. “pXO1-X” is used to represent the 17 gene primers on the pXO1 plasmid. A16PI2D1 (lane 2) lacks specific amplification fragments, while the A16PI2 control (lane 1) generated specific amplification fragments. (B) The authenticity of the pXO2-cured A16Q1D2 strain was confirmed using 12 primer pairs. “pXO2-X” is used to represent the 12 gene primers on the pXO2 plasmid. A16Q1D2 (lane 4) lacks specific amplification fragments, while the A16Q1 control (lane 3) generated specific amplification fragments. (C) Plasmids cured from A16 were authenticated using pXO1-X primers and pXO2-X primers. The pXO2-cured A16MD2 (pXO1+pXO2−) strain (lane 5) lacks specific amplification fragments from pXO2-X primers, but has specific amplification fragments from pXO1-X primers. The pXO1-cured A16MD1(pXO1−pXO2+) strain (lane 6) lacks specific amplification fragments from pXO1-X primers, but has specific amplification fragments from pXO2-X primers. The pXO1 and pXO2 simultaneously-cured A16MDD (pXO1− pXO2−) strain (lane 7) lacks specific amplification fragments from pXO1-X primers and pXO2-X primers.
Figure 6Difference between the active strain and the plasmid-cured strain. (A) Western blot detection of PA expression. M, Prestained protein ladder (PageRuler Prestained Protein Ladder, Product#26616; Thermo Fisher Scientific, Vilnius, Lithuania). SDS-PAGE assay and anti-PA western blotting with two sets of samples: A16PI2 (pXO1+) and A16PI2D1 (pXO1−), and A16MD1 (pXO1−), A16MD2 (pXO1+), and A16MDD (pXO1−). A16PI2D1 (pXO1−) lacks the anti-PA band whereas A16PI2 (pXO1+) has it. A16MD1 (pXO1−) and A16MDD (pXO1−) lack the anti-PA band whereas A16MD2 (pXO1+) has it. (B) Results of bacterial capsule Indian ink staining. One set of samples were A16Q1 and A16Q1D2, and the other were A16, A16MD2, and A16MDD. After dyeing with Indian ink, the background was gray and black. A16Q1D2 lacked any colorless transparent circles around the gray-colored bacteria, whereas A16Q1 had them. A16MD2 and A16MDD lacked any colorless transparent circles around the gray-colored bacteria, whereas A16 had them. pXO2-cured A16Q1D2, A16MD2 and A16MDD lacked capsular structures.
Figure 7Agarose gel electrophoresis of colony PCR for the cured pCE1 plasmid from B. cereus. (A) Colony PCR to identify the strains constructed with spacer-F/R. M, Trans2K Plus II DNA marker. Escherichia coli DH5α containing the pJp1T scissors plasmid was the control. Bacillus cereus BC307 containing pJp1T had the same specific amplification fragment size. (B) Colony PCR to screen for pCE1 plasmid-cured strains with cesB-F/R. M, Trans2K Plus II DNA marker. The pCE1 plasmid-cured strains lack specific amplification fragments, and the curing efficiency was ~69% (lanes 1–3, 5, 7, 9–13, 15, 17–20, 23, 24, 26, and 29–32). (C) Colony PCR to confirm pCE1 plasmid curing using multiple primers. M, Trans2K Plus II DNA marker. cesA, cesB, p1-01, and p1-02 above the short line are 15 gene primers on the pCE1 plasmid. The plasmid p1-cured B. cereus BC307Dp1 (pCE1−) strain (lane 1) lacks specific amplification fragments with cesX primers and p1-X primers, whereas, B. cereus BC307, the active control (lane 2), generated specific amplification fragments.
Figure 8The sterilization efficiency of B. anthracis by using the different sgRNAs. The experimental group was cultured continuously for 3 h and 0.4% D-mannose was added (green arrow). (A) pJART/A16PI2 with single-site sgRNA. The growth curve from the experimental group (pJART/A16PI2 with single-site target sgRNA, with D-mannose, red line) is lower (0.3–0.4) than that of the control group (without D-mannose, blue line) throughout the stationary phase. (B) pJ16ST/A16PI2 with multi-site target sgRNA. The growth curve from the experimental group (pJ16ST/A16PI2 with multi-sites sgRNA, with D-mannose, red line) is lower (0.3–0.6) than that of the control group (without D-mannose, blue line) throughout the stationary phase. (C,D) After incubation with 0.4% D-mannose, the numbers of pJART/A16PI2 colonies were (5.5 ± 2.1) × 105 CFU/mL and (72.5 ± 7.8) × 105 CFU/mL in the induction group and the non-induction group. Values represent the means of at least two independent replicates. Error bars represent standard deviations.
Figure 9Efficiency of B. anthracis sterilization in a mixed culture of B. anthracis and B. cereus under D-mannose induction. (A) The colony counting process used for the mixed strains. Blue balls represent strain pJART/A16PI2 and red balls represent strain pJART/HN001. (B) pJART/A16PI2 and pJART/HN001 grew on LB agar plates (containing 0.5% yolk lotion). The percentage of B. anthracis A16PI2 in the D-mannose-induced group (without proteolytic rings around the colonies) was about 10-fold less than that of the control group. (C) Counts of B. anthracis in the different groups. The black-shaded block denotes B. anthracis pJART/A16PI2 and the white-shaded block denotes B. cereus pJART/HN001. Bacillus anthracis (black-shaded block) accounted for 40% of the bacterial percentage in the D-mannose-induced group, while B. anthracis accounted for 57% in the control group.
Plasmid elimination rates in B. anthracis and B. cereus using the CRISPR/Cas9 system.
| pJO1T | A16PI2 | pXO1 | Yes | 23 | 1 | 96 |
| pJO1NT | No | 22 | 24 | 92 | ||
| pJO2T | A16Q1 | PXO2 | Yes | 24 | 24 | 100 |
| pJO2NT | No | 21 | 24 | 88 | ||
| pJO1T+pJO2T | A16 | pXO1 | Yes | 5 | 12 | 29 |
| pXO2 | 5 | 12 | 29 | |||
| pXO1+pXO2 | 2 | 12 | 14 | |||
| pJN1F2T | A16 | pXO1 | No | 0 | 0 | 0 |
| pXO2 | Yes | 10 | 1 | 91 | ||
| pXO1+pXO2 | 0 | 0 | 0 | |||
| pJF2N1T | A16 | pXO1 | No | 11 | 0 | 100 |
| pXO2 | Yes | 0 | 0 | 0 | ||
| pXO1+pXO2 | 0 | 0 | 0 | |||
| pJN1F2W | A16 | pXO1 | No | 0 | 0 | 0 |
| pXO2 | Yes | 11 | 0 | 100 | ||
| pXO1+pXO2 | 0 | 0 | 0 | |||
| pJF2N1W | A16 | pXO1 | No | 8 | 3 | 73 |
| pXO2 | Yes | 0 | 0 | 0 | ||
| pXO1+pXO2 | 0 | 0 | 0 | |||
| pJp1T | BC307 | BC307 pCE1 | No | 22 | 10 | 69 |